21.74
06-1月-25 16:45:00
15 分の遅延
株式
+0.31
+1.45%
本日の幅
20.55 - 21.99
ISIN
N/A
ソース
NASDAQ
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
08 1 2024 07:00:00 提供 Nasdaq GlobeNewswire
Tourmaline Bio added to the NASDAQ Biotechnology Index
15 12 2023 16:00:00 提供 Nasdaq GlobeNewswire
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
14 12 2023 07:30:00 提供 Nasdaq GlobeNewswire